RESUMEN
OBJECTIVE: Infantile spasms (IS) is a catastrophic childhood seizure disorder that is characterized by extensor and/or flexor spasms, cognitive deterioration and a characteristic EEG abnormality. The latter consists of a pattern of a spike-wave followed by an electrodecremental response (EDR), which is a flattening of the EEG waveform amplitude. The mechanism/circuitry that underpins IS is unknown. Children with Down Syndrome (DS) are particularly vulnerable to IS. The standard mouse model of DS is the Ts65Dn mutant mouse (Ts). Using the Ts mouse, we have created an animal model of IS in DS. This model entails the treatment of Ts mice with a GABABR agonist with a resultant recapitulation of the semiological, electrographic, and pharmacological phenotype of IS. One of the genes triplicated in Ts mice is the kcnj6 gene which codes for the G-protein inwardly rectifying potassium channel 2 (GIRK2) protein. We have shown that over expression of GIRK2 in Ts brain is necessary for the production of the GABABR agonist induced IS phenotype in the Ts mouse. Here, we ask the question whether the excess GIRK2 is sufficient for the production of the GABABR agonist induced IS phenotype. METHODS: To address this question, we used kcnj6 triploid mice, and compared the number of spasms via video analysis and EDR events via EEG to that of the WT mice. RESULTS: We now show that GABARR agonist-treated kcnj6 triploid mice failed to show susceptibility to the IS phenotype. Therefore, over expression of GIRK2 in the brain is necessary, but not sufficient to confer susceptibility to the GABABR agonist-induced IS phenotype in the Ts model of DS. SIGNIFICANCE: It is therefore likely that GIRK2 is working in concert with another factor or factors that are altered in the Ts brain in the production of the GABABR agonist-induced IS phenotype.
Asunto(s)
Síndrome de Down/genética , Síndrome de Down/patología , Canales de Potasio Rectificados Internamente Asociados a la Proteína G/genética , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Anticonvulsivantes/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Síndrome de Down/tratamiento farmacológico , Electroencefalografía , Embrión de Mamíferos , Canales de Potasio Rectificados Internamente Asociados a la Proteína G/metabolismo , Genotipo , Hipocampo/patología , Humanos , Técnicas In Vitro , Lactante , Potenciales de la Membrana/genética , Potenciales de la Membrana/fisiología , Ratones , Ratones Endogámicos C57BL , Técnicas de Placa-Clamp , Péptido Hidrolasas/metabolismo , Quinoxalinas/farmacología , Oxibato de Sodio/farmacología , Espasmos Infantiles/etiología , Trisomía/genéticaRESUMEN
Seizure-induced memory deficits are frequent in patients with temporal lobe epilepsy. However, the neural mechanisms responsible for this memory impairment are not entirely clear. Persistent changes in synaptic efficacy, long-term potentiation (LTP), and depression are considered a cellular substrate underlying the learning and memory processes. Using a lithium-pilocarpine model to induce status epilepticus (SE) in rats, the present study investigated whether the induction of LTP was altered in hippocampal slices obtained 3 h, 1, 3, and 7 days after SE. One week after SE, LTP induction was decreased in hippocampal slices. The reduced plasticity in post-SE tissue was attributable to N-methyl-D-aspartate receptor-dependent LTP. In contrast to control tissue, ifenprodil, a GluN2B-selective antagonist, did not reduce the LTP level in post-SE tissue, suggesting that SE disturbs the functional properties of GluN2B-containing N-methyl-D-aspartate receptors. These changes in synaptic transmission may contribute toward the genesis of epilepsy and seizure-associated memory deficits.
Asunto(s)
Convulsivantes/toxicidad , Hipocampo/efectos de los fármacos , Litio/toxicidad , Potenciación a Largo Plazo/efectos de los fármacos , Pilocarpina/toxicidad , Estado Epiléptico/inducido químicamente , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Anticonvulsivantes/uso terapéutico , Modelos Animales de Enfermedad , Técnicas In Vitro , Técnicas de Placa-Clamp , Ratas , Ratas Wistar , Estado Epiléptico/patología , Estado Epiléptico/prevención & control , Factores de TiempoRESUMEN
BACKGROUND: Gladiolus dalenii Van Geel (Iridaceae) has been used for the treatment of depression and psychotic disorders in African traditional medicine. The aim of this study was to assess the effect of the aqueous extract from the corm of Gladiolus dalenii and its possible mechanisms of action. MATERIALS AND METHODS: We assessed the antidepressant properties of G. dalenii corm aqueous extract in mice, using the open field, forced swimming, and tail suspension tests. Spontaneous locomotor activity of mice given various doses of G. dalenii extract (per os) was determined in the open field, whereas immobility was evaluated in the other two tests. RESULTS: Extract maximal effect was observed at 15 mg/kg, as mice displayed a marked reduction in immobility time in both the forced swimming test (80%) and the tail suspension test (66%). In further studies aimed at investigating the mechanism of action of G. dalenii extract, the latter significantly antagonized the effect of N-methyl-D-aspartate (NMDA, 75 mg/kg) at both the doses 15 mg/kg (p<0.001) and 150 mg/kg (p=0.004). A significant reduction in immobility time was also observed following treatment with combinations of a sub-effective dose of extract (7.5 mg/kg) with either the NMDA receptor antagonist D-(-)-2-amino-7-phosphonoheptanoic acid (D-AP7, 50 mg/kg, P< 0.001), the serotonin reuptake inhibitor fluoxetine (5 and 10 mg/kg, P< 0.001 and P< 0.001 respectively), and the multi-target antidepressant imipramine (5 and 10 mg/kg, P< 0.001 and P< 0.001 respectively). Moreover, neither G. dalenii extract alone nor its combinations with NMDA ligands imipramine and fluoxetine enhanced mouse spontaneous locomotor activity. CONCLUSION: Altogether, these results suggest that G. dalenii has antidepressant properties, probably mediated through interactions with NMDA, serotonin and/ or noradrenergic systems, and may justify its use in traditional medicine.
Asunto(s)
Antidepresivos/uso terapéutico , Depresión/tratamiento farmacológico , Iridaceae , Actividad Motora/efectos de los fármacos , Fitoterapia , Extractos Vegetales/uso terapéutico , Estrés Psicológico/tratamiento farmacológico , 2-Amino-5-fosfonovalerato/análogos & derivados , 2-Amino-5-fosfonovalerato/farmacología , 2-Amino-5-fosfonovalerato/uso terapéutico , Inhibidores de Captación Adrenérgica/farmacología , Inhibidores de Captación Adrenérgica/uso terapéutico , Animales , Antidepresivos/farmacología , Fluoxetina/farmacología , Suspensión Trasera , Imipramina/farmacología , Masculino , Medicinas Tradicionales Africanas , Ratones , N-Metilaspartato/antagonistas & inhibidores , Extractos Vegetales/farmacología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , NataciónRESUMEN
The widely-held assumption was that oxidative stress does not occur during seizures in the immature brain. The major finding of the present study concerns evidence of oxidative stress in the brain of immature rats during seizures induced by DL-homocysteic acid. Seizures were induced in 12-day-old rats by bilateral intracerebroventricular infusion of DL-homocysteic acid (DL-HCA, 600 nmol/side) and oxidative stress was evaluated by in situ detection of superoxide anion (O(2)·(-)). Using hydroethidine (Het) method, the fluorescent signal of the oxidized products of Het (reflecting O(2)·(-) production) significantly increased (by 50%-60%) following 60 min lasting seizures in all the studied structures, namely CA1, CA3 and dentate gyrus of the hippocampus, cerebral cortex and thalamus. The enhanced O(2)·(-) production was substantially attenuated or completely prevented by substances providing an anticonvulsant effect, namely by a competitive NMDA receptor antagonist AP7, a highly selective and potent group II metabotropic glutamate receptor (mGluR) agonist 2R,4R-APDC and highly selective group III mGluR, subtype 8 agonist (S)-3,4-DCPG. Complete protection was achieved by two SOD mimetics Tempol and MnTMPYP which strongly suggest that the increased fluorescent signal reflects O(2)·(-) formation. In addition, both scavengers provided a partial protection against brain damage associated with the present model of seizures. Signs of neuronal degeneration, as evaluated by Fluoro-Jade B staining, were detected at 4h following the onset of seizures. The present findings thus suggest that the increased superoxide generation precedes neuronal degeneration and may thus play a causative role in neuronal injury. Occurrence of oxidative stress in brain of immature rats during seizures, as demonstrated in the present study, can have a clinical relevance for a novel approach to the treatment of epilepsy in children, suggesting that substances with antioxidant properties combined with the conventional therapies might provide a beneficial effect.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Encéfalo/metabolismo , Convulsiones/patología , Convulsiones/prevención & control , Superóxidos/metabolismo , 2-Amino-5-fosfonovalerato/análogos & derivados , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Animales Recién Nacidos , Encéfalo/efectos de los fármacos , Modelos Animales de Enfermedad , Homocisteína/análogos & derivados , Homocisteína/toxicidad , Infusiones Intraventriculares , Masculino , Metaloporfirinas/metabolismo , Prolina/análogos & derivados , Prolina/uso terapéutico , Ratas , Ratas Wistar , Convulsiones/inducido químicamente , Estadísticas no Paramétricas , Factores de TiempoRESUMEN
The neuropeptide galanin (Gal) and its receptors (GalR1, GalR2, and GalR3) are expressed in spinal cord. We have characterized the pharmacology of the antinociceptive effects of intrathecally (i.t.) administered galanin and its analogs in the formalin test in rats, using an automated flinch detection system. Intrathecal injection of rat galanin (Gal(1-29)) or human galanin (Gal(1-30)) produced a dose-dependent inhibition of formalin-evoked flinching in phase 2, but not in phase 1. Relative potency of galanin homologs is Gal(1-29) >or= Gal(1-30) > galanin-like peptide(1-24) >or= Gal(2-11) = Gal (3-29) (an inactive analog). Galanin(1-29) and Gal(1-30) are both high-affinity agonists to GalR1/R2, whereas Gal(2-11) is a GalR2 receptor agonist. Our data suggest that i.t. galanin-produced antinociception is mediated by activation of GalR1 receptors. When comparing antinociceptive effects of i.t. Gal(1-29) to morphine and to 2-amino-5-phosphonopentanoic acid (AP-5, an N-methyl-d-aspartate antagonist), Gal(1-29) is of intermediate potency between these two analgesic agents based on the ED(50) values. An isobolographic analysis showed synergy between Gal(1-29) and morphine and between Gal(1-29) and AP-5 on the second phase. Fixed ratio dose combinations of morphine and Gal(1-29), or AP-5 and Gal(1-29) produced significantly greater antinociception than predicted from simple additivity. In summary, the present findings reveal that 1) spinal galanin produces a reliable inhibition of formalin-induced facilitated nociceptive processing, an effect possibly mediated by GalR1 receptors; and 2) galanin potentiates i.t. morphine and AP-5-induced antinociception.
Asunto(s)
2-Amino-5-fosfonovalerato/farmacología , Analgésicos/farmacología , Galanina/farmacología , Morfina/farmacología , Dolor/tratamiento farmacológico , Receptor de Galanina Tipo 1/metabolismo , Médula Espinal/efectos de los fármacos , 2-Amino-5-fosfonovalerato/uso terapéutico , Analgésicos/uso terapéutico , Animales , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Galanina/análogos & derivados , Galanina/uso terapéutico , Inyecciones Espinales , Masculino , Morfina/uso terapéutico , Ratas , Ratas Sprague-Dawley , Receptor de Galanina Tipo 1/efectos de los fármacosRESUMEN
In the present study, the interaction between a noncompetitive [(+)-MK-801] and a competitive (CGP 40116) NMDA receptor antagonists was tested in two different behavioral paradigms: locomotor activity test and prepulse inhibition of the acoustic startle reflex. Additionally, their effects on working memory and selective attention were evaluated in the delayed alternation task. All above paradigms served to model the symptoms of schizophrenia. It was found that locomotor stimulatory effect of (+)-MK-801 (0.4 mg/kg) was antagonized by prior administration of CGP 40116 (5 mg/kg). Lower doses of CGP 40116 (1.25 and 2.5 mg/kg) were ineffective. CGP 40116 given alone did not influence locomotor activity in rats. It was also shown that CGP 40116 antagonized the disruption of the process of sensorimotor gating evoked by (+)-MK-801. On the contrary, both CGP 40116 and (+)-MK-801 increased a number of errors in the delayed alternation test revealing detrimental effect of CGP 40116 on spatial working memory and selective attention even at a lower dose than that required to antagonize the effects of (+)-MK-801. The presented results indicate that noncompetitive and competitive NMDA receptor antagonists, when used at relatively low doses, may produce qualitatively different behavioral effects, as evidenced by the experiments with locomotor activity and prepulse inhibition. Moreover, the competitive NMDA receptor antagonists may even inhibit some psychotomimetic effects related to the noncompetitive blockade of this receptor. However, therapeutic potential of CGP 40116, a competitive NMDA receptor antagonist, should be considered with caution since in the range of doses effective against the psychotomimetic effects of (+)-MK-801, it impairs rats' performance in the delayed alternation paradigm, i.e. it worsens efficacy of working memory.
Asunto(s)
2-Amino-5-fosfonovalerato/análogos & derivados , 2-Amino-5-fosfonovalerato/uso terapéutico , Maleato de Dizocilpina/efectos adversos , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Esquizofrenia/inducido químicamente , Esquizofrenia/tratamiento farmacológico , 2-Amino-5-fosfonovalerato/antagonistas & inhibidores , 2-Amino-5-fosfonovalerato/farmacología , Estimulación Acústica/efectos adversos , Animales , Modelos Animales de Enfermedad , Maleato de Dizocilpina/administración & dosificación , Maleato de Dizocilpina/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Inhibición Neural/efectos de los fármacos , Ratas , Ratas Wistar , Receptores de N-Metil-D-Aspartato/efectos de los fármacos , Reflejo de Sobresalto/efectos de los fármacos , Reflejo de Sobresalto/fisiologíaRESUMEN
The anticonvulsant potency of the competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, 2-amino-7-phosphonoheptanoic acid (APH) was investigated in the model of epilepsy induced by systemic administration of metaphit (1-(1-(3-isothiocyanatophenyl)-cyclohexyl)-piperidine). Male Wistar rats were injected with metaphit intraperitoneally (10 mg/kg, i.p.) and exposed to intense audio stimulation (electric bell generating 100 +/- 3 dB at animal level for 60 s) one hour after administration and at 1-h intervals thereafter. Audiogenic seizures consisted of wild running followed by clonic and tonic convulsions. The incidence and severity of seizures increased with time, reaching a peak 7-12 h after metaphit administration, and then gradually decreased until 31 h, when no animal responded. APH was injected intracerebroventricularly (0.005; 0.01; 0.02; 0.03 and 0.05 micromole i.c.v. in 5 microl of sterile saline) after 8 hours of seizure responses. APH inhibited seizures in a dose-dependent manner. Minimum dose which completely blocked seizures in all animals was 0.03 micromole. After varying periods of time, seizures reappeared. The present results demonstrate that APH acts as anticonvulsant in metaphit's model of audiogenic seizures in rats.
Asunto(s)
2-Amino-5-fosfonovalerato/análogos & derivados , Anticonvulsivantes/uso terapéutico , Convulsiones/tratamiento farmacológico , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Masculino , Fenciclidina/análogos & derivados , Ratas , Ratas Wistar , Convulsiones/inducido químicamenteRESUMEN
BACKGROUND: The present study was designed to investigate in a focal cerebral ischemia model the influence of 2APH, a competitive NMDA receptor antagonist, on the cerebral blood flow of cat cortex, given intravenously before cerebral ischemia. METHODS: Thirty-four male cats weighing 2.5 to 3.5 kg were anesthetized with halothane and then randomly assigned to either control or experimental group. In the experimented group 18 cats were treated with 2APH and in the control group 16 cats were given saline 10 min before middle cerebral artery occlusion (MCAO). Cortical blood flow (CBF), determined by laser Doppler ultrasound flowmetry, was measured 1 h, 2 h, 3 h, 4 h and 5 h after occlusion. Infarct volume was calculated by summing up the areas in each stained brain section after the experiment. RESULTS: There was a significant difference in the infarct volume of cortex between the 2APH group and the saline control group (P < 0.05). Moreover, we did notice an apparent decrease of the infarct volume in basal ganglia area when 2APH was given (P < 0.01). The total infarct volume was significantly smaller in the group treated with 2APH after MCAO as compared with the saline control group (P < 0.01). CONCLUSIONS: The data from the present experiment suggest that NMDA antagonists may not only antagonize the neurotoxic effect of excitatory amino acid on ischemic neuron but also improve the CBF of ischemic brain.
Asunto(s)
2-Amino-5-fosfonovalerato/análogos & derivados , 2-Amino-5-fosfonovalerato/uso terapéutico , Isquemia Encefálica/tratamiento farmacológico , Circulación Cerebrovascular/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , 2-Amino-5-fosfonovalerato/farmacología , Animales , Isquemia Encefálica/fisiopatología , Gatos , MasculinoRESUMEN
The influence of non-competitive NMDA receptor antagonist, 1-amino-3,5-dimethyl-adamantane (memantine), and glycineB site antagonist, 7-chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolone (L-701,324), on the development of ethanol dependence was investigated in Wistar rats. The development of ethanol dependence was induced by intragastric administration of 20% w/v ethanol, three times a day at increasing doses. The results were quantified using withdrawal audiogenic seizures, 12 h after the last ethanol administration. Memantine (3.75 or 7.5 mg/kg) and L-701,324 (2.5 or 5 mg/kg), given before ethanol administration, prevented the development of ethanol dependence. Our results support the data that NMDA receptors are involved in the development of ethanol dependence.
Asunto(s)
Trastornos Relacionados con Alcohol/tratamiento farmacológico , Etanol/farmacología , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Memantina/uso terapéutico , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , 2-Amino-5-fosfonovalerato/administración & dosificación , 2-Amino-5-fosfonovalerato/farmacología , 2-Amino-5-fosfonovalerato/uso terapéutico , Adaptación Biológica , Animales , Modelos Animales de Enfermedad , Etanol/administración & dosificación , Antagonistas de Aminoácidos Excitadores/administración & dosificación , Antagonistas de Aminoácidos Excitadores/farmacología , Masculino , Memantina/administración & dosificación , Quinolonas/administración & dosificación , Quinolonas/farmacología , Quinolonas/uso terapéutico , Ratas , Ratas Wistar , Receptores de N-Metil-D-Aspartato/metabolismo , AutoadministraciónRESUMEN
The influence of APV ((+/-)-2-amino-5-phosphonovaleric acid) on EEG activity and behavior was studied on a model of epilepsy induced by intraperitoneal administration of metaphit (1-(1-(3-isothiocyanatophenyl)-cyclohexyl)-piperidine). Male Wistar rats received an injection of metaphit (10 mg/kg) and were subjected to intense audio stimulation (100+/-3 dB, 60 s) at hourly intervals during the experiment. The seizures were classified according to a four point scale ranging from 0 (no seizure) to 3 (tonic convulsions). In our report we studied the time course which revealed the maximum incidence and severity of seizures 7-12 h after the injection (10 out of 12 rats, with severity of 2.25+/-0.32). APV (0.05, 0.1, 0.2 and 0.3 micromol) was injected intracerebroventricularly at the time of fully developed convulsions. APV inhibited seizures in a dose-dependent manner. The minimum dose, which completely blocked seizures in all animals, was 0.3 micromol, while ED50 were 0.11, 0.10 and 0.07 micromol against running, clonus and tonus, respectively. In contrast to behavioral inhibition of convulsions, metaphit-provoked epileptiform activity was not abolished by APV, and represented a prerequisite for the reappearance of behavioral seizures. It is suggested that APV is rather an anticonvulsant than an antiepileptic agent in this model of epilepsy.
Asunto(s)
2-Amino-5-fosfonovalerato/farmacología , Epilepsia Refleja/tratamiento farmacológico , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Relación Dosis-Respuesta a Droga , Epilepsia Refleja/inducido químicamente , Masculino , Fenciclidina/análogos & derivados , Ratas , Ratas WistarRESUMEN
High pressure induced locomotor and motor hyperactivities (LMA), tremor and myoclonia in rat. The LMA has been reported to be reduced by intracerebroventricular (i.c.v.) administration of dopaminergic receptor antagonists. Moreover, the LMA but not myoclonia correlate with pressure induced striatal dopamine increase. Nevertheless the role of dopaminergic and NMDA receptor activities at striatal level in the development of LMA remained unclear. In this study, the microdialysis technique associated to a behavioural device was used to test the effects of intra-striatal administration of D1 antagonist SCH23390 (1 microM), D2 antagonist sulpiride (1 microM) and NMDA antagonist AP-5 (10 microM) on LMA, tremor and myoclonia expression. Data clearly showed that LMA was drastically reduced by each treatment. In contrast, tremor and myoclonia were poorly affected. These data suggest that both dopaminergic and NMDA receptor activities at striatal level are needed for the full expression of the pressure-induced LMA and confirm that striatal neurotransmission changes are principally involved in this behavioural disorders. At the light of recent studies on dopaminergic neurotransmission and glutamate evoked-NMDA activity, we suggest that blockage of D1 or D2 receptors should reduced the LMA by reducing glutamate-evoked activity.
Asunto(s)
Antagonistas de Dopamina/uso terapéutico , Antagonistas de Aminoácidos Excitadores/farmacología , Síndrome Neurológico de Alta Presión/tratamiento farmacológico , Hipercinesia/tratamiento farmacológico , Mioclonía/tratamiento farmacológico , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Temblor/tratamiento farmacológico , 2-Amino-5-fosfonovalerato/farmacología , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Benzazepinas/farmacología , Benzazepinas/uso terapéutico , Cuerpo Estriado/efectos de los fármacos , Antagonistas de Dopamina/farmacología , Antagonistas de los Receptores de Dopamina D2 , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Síndrome Neurológico de Alta Presión/fisiopatología , Hipercinesia/fisiopatología , Masculino , Microdiálisis , Mioclonía/fisiopatología , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D1/antagonistas & inhibidores , Sulpirida/farmacología , Sulpirida/uso terapéutico , Temblor/fisiopatologíaRESUMEN
Male Wistar albino rats were subjected to sound stimulation (100+/-3 dB, 60 s) at hourly intervals after intraperitoneal injection of metaphit (10 mg kg-1). The incidence and severity of audiogenic convulsions increased with time, reached a peak 7-12 h after metaphit administration (ten out of 12 and 2.25+/-0.32), and then gradually decreased until 31 h post-injection when no animal displayed signs of seizure. In order to test anticonvulsant activity on fully developed seizures, antagonists were delivered intracerebroventricularly after the 8th testing. The doses of AP7 were 0.005, 0.01, 0.02, 0.03 and 0.05 micromol, and 0.05, 0.1, 0.2 and 0.3 micromol of AP5, all in 5 microliters of physiological saline. Antagonists inhibited metaphit-induced audiogenic seizures in a dose-related fashion. The minimum doses that completely abolished convulsions were 0.03 and 0.3 micromol for AP7 and AP5, respectively. For suppression of running, clonus and tonus AP7 was 16-18 times more potent than AP5. These results indicate that AP7 is substantially more potent than AP5 against all phases of metaphit-induced audiogenic seizures in rats. (c) 1998 The Italian Pharmacological Society.
Asunto(s)
2-Amino-5-fosfonovalerato/análogos & derivados , 2-Amino-5-fosfonovalerato/uso terapéutico , Anticonvulsivantes/uso terapéutico , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Convulsiones/tratamiento farmacológico , Estimulación Acústica , Animales , Masculino , Fenciclidina/análogos & derivados , Ratas , Ratas Wistar , Convulsiones/etiologíaRESUMEN
The effect of the noncompetitive N-methyl-d-aspartate (NMDA)-receptor antagonist MK-801 on seizures induced by hyperbaric oxygen in relation to changes in cerebral blood flow (CBF) was investigated. Rats were injected with MK-801 (0.005-8 mg/kg) 30 min before exposure to 100% O2 at 5 atm (gauge pressure). MK-801 administration resulted in a biphasic response in seizure latency. Doses of 0.1-4 mg/kg significantly decreased time to EEG and motor seizures, while 8 mg/kg had no effect on seizure latency. MK-801 had no effect on seizure duration. In a dose range 0.1-8 mg/kg MK-801 increased CBF in awake animals, which might be responsible for the decreased seizure latency. The gradual increase in seizure latency with increasing MK-801 doses suggests involvement of an additional factor probably related to the drug's anticonvulsive effect. Unlike MK-801, a competitive NMDA receptor antagonist, AP-7, at a dose 250 mg/kg had no effect on latency to seizures or CBF.
Asunto(s)
Maleato de Dizocilpina/farmacología , Oxigenoterapia Hiperbárica , Fármacos Neuroprotectores/farmacología , Convulsiones/tratamiento farmacológico , 2-Amino-5-fosfonovalerato/análogos & derivados , 2-Amino-5-fosfonovalerato/farmacología , 2-Amino-5-fosfonovalerato/uso terapéutico , Análisis de Varianza , Animales , Anticonvulsivantes/farmacología , Anticonvulsivantes/uso terapéutico , Corteza Cerebral/irrigación sanguínea , Corteza Cerebral/efectos de los fármacos , Circulación Cerebrovascular , Maleato de Dizocilpina/uso terapéutico , Electroencefalografía/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Masculino , Fármacos Neuroprotectores/uso terapéutico , Ratas , Ratas Sprague-Dawley , Convulsiones/etiología , Convulsiones/fisiopatologíaRESUMEN
Amputation of the mouse tail tip (2.5 cm) caused long term thermal and mechanical hyperalgesia in the remaining part of the tail. Hyperalgesia of the hindpaw to noxious heat (55 degrees C) and cold (0 degrees C) stimuli were also observed. Hyperalgesia at both the tail and hindpaw had a rapid onset (< or = 30 min) and long lasting (> or = 7 days) effect. Skin temperature of the remaining tail or hindpaw was not significantly affected by the amputation. Heat injury of the tail in normal mice induced short but not long term hyperalgesia (< or = 48 h). Intrathecal pretreatment with NMDA receptor antagonists significantly attenuated long term hyperalgesia caused by tail amputation. These results strongly suggest that spinal NMDA receptors are critical for the induction of hyperalgesia by tail amputation, and the current mouse model may prove useful for investigating mechanisms of persistent pain after amputation.
Asunto(s)
Amputación Quirúrgica/efectos adversos , Hiperalgesia/fisiopatología , Umbral del Dolor/fisiología , Receptores de N-Metil-D-Aspartato/fisiología , 2-Amino-5-fosfonovalerato/farmacología , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Maleato de Dizocilpina/farmacología , Maleato de Dizocilpina/uso terapéutico , Antagonistas de Aminoácidos Excitadores/farmacología , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/etiología , Inyecciones Espinales , Masculino , Ratones , Ratones Endogámicos C57BL , Umbral del Dolor/efectos de los fármacos , Cola (estructura animal)RESUMEN
The hexachlorophene-induced cytotoxic brain oedema is an experimental model of brain damage, suitable for testing cerebroprotective substances (Andreas 1993). In order to examine whether glutamate receptors are involved in mediating functional disorders due to neurotoxic brain damage, we have studied the protective effects of several competitive and non-competitive antagonists using adult male Wistar rats in a simple "ladder-test" for assessing coordinative motor behaviour. Hexachlorophene-induced brain damage was verified by histological examination of the cerebellum with vacuolation of white matter, astrocyte hypertrophy and astrocyte proliferation taken as signs of neurotoxic injury. The non-competitive N-methyl-D-aspartate (NMDA) antagonist dizocilpine maleate (MK-801) decreased the motor disturbance on the first and second day of the "ladder-test" when applied in the doses 0.1 mg/kg and 0.2 mg/kg intraperitoneally for 3 weeks during the hexachlorophene treatment. Acute MK-801 administration (0.1 mg/kg intraperitoneally) after 3 weeks hexachlorophene exposure improved the coordinative motor response only on the first day. When testing the competitive NMDA receptor antagonist 2-amino-5-phosphonopentanoic acid (AP-5) in the dose 1.0 mg/kg intraperitoneally the motor disturbance was lowered significantly earlier than in spontaneous remission. Similar effects were observed with 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) in the dose of 0.8 mg/kg intraperitoneally, an antagonist interacting both with the strychnine-insensitive binding site for glycine within the NMDA receptor complex and with the kainate(+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor complex. Concurrent MK-801 administration decreased the vacuolation of white matter. The results suggest that NMDA receptors and non-NMDA receptors are involved in development of functional disorders induced by hexachlorophene.
Asunto(s)
Edema Encefálico/tratamiento farmacológico , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Receptores de Glutamato/efectos de los fármacos , 2-Amino-5-fosfonovalerato/uso terapéutico , 6-Ciano 7-nitroquinoxalina 2,3-diona/uso terapéutico , Animales , Encéfalo/efectos de los fármacos , Encéfalo/patología , Edema Encefálico/inducido químicamente , Edema Encefálico/patología , Maleato de Dizocilpina/uso terapéutico , Hexaclorofeno , Masculino , Ratas , Ratas WistarRESUMEN
To reveal possible involvement of NK-1 substance P receptors and N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptors in the production of inflammatory hyperalgesia, we examined the effects of intrathecal injections of antagonists at those receptors on the nociceptive threshold of inflammatory hyperalgesic rats in the paw-pressure test. Intrathecal injections of the NK-1 antagonist CP-96,345 (0.3-3 nmol/rat), the NMDA antagonist D-2-amino-5-phosphonovaleric acid (D-APV, 1-10 nmol/rat), and the non-NMDA antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 1-10 nmol/rat) dose-dependently suppressed adjuvant- and carrageenin-induced hyperalgesia, without effect on the nociceptive threshold of non-inflamed paws. Furthermore, to estimate whether inflammatory hyperalgesia is accompanied with an alteration of the responsiveness to substance P and excitatory amino acids, we examined the effects of injections of complete Freund's adjuvant (intradermal) and carrageenin (subcutaneous) on the aversive responses to intrathecal substance P and excitatory amino acid agonists. Both injections significantly potentiated the aversive behaviors elicited by intrathecal injections of excitatory amino acid agonists, NMDA (1 nmol/rat), a-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA, 1 nmol/rat) and kainate (1 nmol/rat), but not those by substance P. The present results suggest that the enhancement of synaptic transmission mediated by substance P and excitatory amino acids in the spinal dorsal horn is at least partly involved in the production of inflammatory hyperalgesia, and that such a hyperalgesia is accompanied with the enhanced responsiveness to excitatory amino acids through NMDA and non-NMDA receptors, but not with changes in responsiveness to substance P.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Agonistas de Aminoácidos Excitadores/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , Hiperalgesia/etiología , Antagonistas del Receptor de Neuroquinina-1 , Umbral del Dolor/efectos de los fármacos , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Sustancia P/antagonistas & inhibidores , 2-Amino-5-fosfonovalerato/farmacología , 2-Amino-5-fosfonovalerato/uso terapéutico , 6-Ciano 7-nitroquinoxalina 2,3-diona/farmacología , 6-Ciano 7-nitroquinoxalina 2,3-diona/uso terapéutico , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Compuestos de Bifenilo/farmacología , Compuestos de Bifenilo/uso terapéutico , Carragenina , Relación Dosis-Respuesta a Droga , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Adyuvante de Freund , Hiperalgesia/inducido químicamente , Hiperalgesia/tratamiento farmacológico , Masculino , Ratas , Ratas Sprague-Dawley , Médula Espinal/efectos de los fármacos , Médula Espinal/metabolismo , Sustancia P/agonistasRESUMEN
BACKGROUND: Evidence from experiments by others indicates an important role for excitatory amino acids activating spinal n-methyl-d-aspartate (NMDA) receptors in models of persistent pain. The purpose of this study was to examine the effect of intrathecal (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine (MK-801), a noncompetitive NMDA receptor antagonist, 2-amino-5-phosphonovaleric acid (AP5), a competitive NMDA receptor antagonist, and N-G-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, on pain behaviors in a rat model of postoperative pain. METHODS: Rats with intrathecal catheters were anesthetized and underwent a plantar incision. Withdrawal threshold to punctate stimulation applied adjacent to the wound, response frequency to application of a nonpunctate stimulus applied directly to the wound, and nonevoked pain behaviors were measured before and after intrathecal administration of MK-801 or AP5. The effect of intrathecal L-NAME on mechanical hyperalgesia was also examined. RESULTS: Mechanical hyperalgesia increased and was persistent after plantar incision and was not decreased by intrathecal administration of 4, 14, or 40 nmol MK-801 or 10 nmol AP5. Only the greatest dose of AP5, 30 nmol, caused a small decrease in punctate and nonpunctate hyperalgesia. Intrathecal L-NAME had no effect. Neither intrathecal MK-801 nor intrathecal AP5 affected nonevoked pain behaviors. The greatest doses caused motor deficits. CONCLUSIONS: Unlike intrathecal and systemic morphine, intrathecal NMDA receptor antagonists did not modify pain behaviors in this rat model of postoperative pain. These data suggest that NMDA receptors do not play an important role in the maintenance of postoperative pain behaviors and that NMDA receptor antagonists, administered spinally by themselves during the postoperative period, will not be useful for the treatment of postoperative pain in humans.
Asunto(s)
Antagonistas de Aminoácidos Excitadores/uso terapéutico , Dolor Postoperatorio/tratamiento farmacológico , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Médula Espinal/efectos de los fármacos , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Maleato de Dizocilpina/uso terapéutico , Antagonistas de Aminoácidos Excitadores/administración & dosificación , Hiperalgesia/tratamiento farmacológico , Masculino , Actividad Motora/efectos de los fármacos , NG-Nitroarginina Metil Éster/farmacología , Ratas , Ratas Sprague-DawleyRESUMEN
The effects of the non-competitive antagonists of the glutamate complex receptor, dizocilpine (MK 801) and ketamine and of the competitive antagonist CGP 39551 were examined on the induction of tolerance to morphine, the development of physical dependence and the expression of the abstinence syndrome to the opiate in mice. Morphine was administered in a single dose (300 mg/kg) of a slow release preparation. Dizocilpine (0.005 or 0.01 mg/kg given at 3, 12 and 24 h after the priming dose of morphine), ketamine (2, 4 or 8 mg/kg, 30 min before and 3, 6, 9 and 24 h after the priming dose) and DL-(E)-2-amino-4-methyl-5-phosphonopentanoate carboxy-ethylester (CGP 39551) (1.5 or 3 mg/kg, but not 6 or 12 mg/kg 30 min before and 12 and 24 h after the priming dose) reduced the intensity of tolerance to, and physical dependence on morphine. The drugs also reduced the intensity of the abstinence behaviour when given in a single dose, 30 min before (s.c.) naloxone (4 mg/kg)-precipitated withdrawal syndrome in mice chronically treated with morphine. Thus, the results of this study indicate that competitive and non-competitive NMDA receptor antagonists prevent morphine tolerance and decrease the development of physical dependence on the opiate in mice.
Asunto(s)
Antagonistas de Aminoácidos Excitadores/uso terapéutico , Dependencia de Morfina/prevención & control , Morfina/efectos adversos , 2-Amino-5-fosfonovalerato/análogos & derivados , 2-Amino-5-fosfonovalerato/farmacología , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Maleato de Dizocilpina/farmacología , Maleato de Dizocilpina/uso terapéutico , Tolerancia a Medicamentos , Antagonistas de Aminoácidos Excitadores/farmacología , Ketamina/farmacología , Ketamina/uso terapéutico , Masculino , Ratones , Dependencia de Morfina/fisiopatología , Dimensión del Dolor , Síndrome de Abstinencia a Sustancias/fisiopatología , Síndrome de Abstinencia a Sustancias/prevención & controlRESUMEN
In this study we evaluated the effect of the competitive N-methyl-D-aspartate (NMDA) antagonist D-(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CGP 40116) on both early (2 days) and late (28 days) ischemic brain damage in a rodent model of focal cerebral ischemia by means of magnetic resonance imaging (MRI) and conventional histology. Immediately after occlusion of the left middle cerebral artery (MCA), rats received either CGP 40116 (20 mg/kg i.p.) or isotonic saline. Two MRI scans were performed in each animal 2 and 28 days after MCA occlusion. After the second scan, rats were perfusion fixed for histological evaluation. The volume of lesioned brain tissue as determined by MRI or histology was calculated from the damaged area in single sections and the distance between them. CGP 40116 reduced acute infarct volume as measured by MRI 2 days after MCA occlusion by 44% (p < 0.05, analysis of variance). After 28 days the lesion detected by MRI was still significantly smaller in the drug-treated animals. This finding was confirmed by the histological analysis showing a 64% reduction in the volume of brain atrophy in the CGP 40116 group (p < 0.05, analysis of variance). There was a good correlation between the MRI data and the results of the histological evaluation (r = 0.9). Our results indicate that (a) the competitive NMDA antagonist CGP 40116 permanently protects brain tissue from the consequences of cerebral ischemia in a rat model for human stroke and (b) early and late pathological changes can be accurately measured by MRI.
Asunto(s)
2-Amino-5-fosfonovalerato/análogos & derivados , Ataque Isquémico Transitorio/tratamiento farmacológico , N-Metilaspartato/antagonistas & inhibidores , 2-Amino-5-fosfonovalerato/administración & dosificación , 2-Amino-5-fosfonovalerato/uso terapéutico , Animales , Encéfalo/metabolismo , Encéfalo/patología , Arterias Cerebrales , Constricción , Proteína Ácida Fibrilar de la Glía/metabolismo , Ataque Isquémico Transitorio/metabolismo , Ataque Isquémico Transitorio/patología , Imagen por Resonancia Magnética , Masculino , Ratas , Ratas Endogámicas F344RESUMEN
The antidepressant properties of the non-competitive NMDA receptor antagonist, MK-801 (dizocilpine), and the competitive NMDA receptor antagonist, CGP 37849 (DL-(E)-2-amino-4-methyl-5-phosphono-3-pentonoic acid) and its (R)-enantiomer CGP 40116, were studied in a chronic mild stress model of depression. In this model, animals subjected to a variety of mild stressors for a prolonged period of time show a substantial decrease in the consumption of palatable sucrose solution (anhedonia). It was previously demonstrated that the chronic mild stress-induced anhedonia can be reversed by chronic treatment with various antidepressant drugs. In this study we found that the stress-induced deficit in sucrose intake was gradually reversed by chronic (4-5 weeks) treatment with MK-801 (0.3 mg/kg i.p.), CGP 37849 (5 mg/kg i.p.) and CGP (25 mg/kg p.o.). The magnitude of this effect and its time course were comparable to those observed following similar administration of imipramine (10 mg/kg i.p. or p.o.). The increase in sucrose intake following chronic administration of imipramine and NMDA receptor antagonists was specific to stressed animals; the behaviour of non-stressed controls was unchanged by any of the drugs tested. These results confirm those of previous studies, carried out on 'normal' animals, suggesting that antagonists of NMDA receptors may have antidepressant properties.